NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

GlobeNewswireOct 7 11:00 ET

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02 for Patients Afflicted With Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

GlobeNewswireAug 5 11:00 ET

NeOnc Technologies Receives FDA Approval to Expand NEO100-01 Phase 2a Clinical Trial to Include Patients With Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

GlobeNewswireJul 16 11:15 ET

Express News | Neonc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

ReutersJun 26 16:39 ET

NeOnc Technologies Holdings Files to Withdraw IPO

Dow JonesJun 12 13:20 ET

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

GlobeNewswireMay 15 11:00 ET